Amgen (AMGN)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-30
$466.01+1.15%
Close 2026-10-30 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-30
Research Workspace
Put AMGN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS near guidance mid-point: Diluted EPS: $4.37 per share.
View ThesisRevenue growth is slowing — up about 9% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 14%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 36% growth a year, above the roughly 5% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskAmgen’s case rests on MariTide’s progress through Phase 3 trials, alongside strengthening revenue growth. Revenue growth accelerated from 6% to 10% year over year, and Q2 FY2026 earnings beat consensus. Amgen trades at 21× P/E versus a 22× peer median, above its 18× historical multiple. The market is pricing in more growth than our forecast, so expectations look full. The risk is premium compression if the growth case does not justify the multiple. Our model puts the next-quarter miss probability near 10%. Peer multiples imply a price about 36% below where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. AMGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 34 analysts currently covering AMGN (as of Oct 2026).
Based on 18 Wall Street analysts offering 12-month price targets for AMGN in the last 4 months.
Continue this research
Compare AMGN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AMGN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put AMGN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Deliver long-term growth through innovation
Positive Tezspire trial results support innovation-led growth, though commercial and regulatory impact remains uncertain.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $466.01
The last 12 months of price, then the range of analyst 12-month targets from today’s $466.01.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Loss of a key leader may impact innovation and execution.
Increased price target reflects confidence in pipeline growth.
Threatens: Manage capital through disciplined debt issuance and allocation
Dividend raise indicates potential capital allocation challenges.
Advances: Advance MariTide through Phase 3 clinical trials
Positive results support advancement of MariTide in trials.
Advances: Advance MariTide through Phase 3 clinical trials
Advances product pipeline with potential new therapy for Sjögren's.
Advances: Advance MariTide through Phase 3 clinical trials
Positive trial results enhance product pipeline and growth potential.
Advances: Advance MariTide through Phase 3 clinical trials
Highlights progress on MariTide aligns with product advancement goals.
